CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2085 tablets for the treatment of uncomplicated influenza A and B in adults and adolescents age 12 years and older.
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their blood. Yet that reality is limited to those with access to treatment. More than 40 million people worldwide live with HIV, with over a million new infections and hundreds of thousands of deaths each year, underscoring that major challenges remain.
The U.S. CDC has adopted the recommendations of its Advisory Committee for Immunization Practices (ACIP) regarding the hepatitis B virus (HBV) vaccine scheduling for infants, determining that immunization should be an individual-based decision rather than the universal birth dosing practice that has been in place for the past 30 years.
